NMN and NAD+ supplements: what the randomized trials actually show

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every living cell. It is required for the enzymatic reactions that convert food into usable cellular energy, and it fuels a separate family of enzymes, including sirtuins and PARPs, involved in DNA repair and cellular stress responses. In animal models, tissue NAD+ levels fall measurably with age, and restoring them in old or diseased animals has improved a range of health measures. That preclinical picture is the entire rationale behind the NAD+ supplement market.^[1]

NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are the two “precursor” molecules sold as supplements on the premise that the body converts them into NAD+ more efficiently than plain niacin. Both are unregulated dietary supplements, not FDA-approved drugs, typically sold at doses from 250mg to 2,000mg per day and marketed with claims touching energy, cognition, muscle mass, and slowing aging itself.

This is a familiar pattern on this site: a compound with genuinely interesting animal data attracts a fast-moving supplement or off-label market well before human trial evidence catches up. We saw the same dynamic in our coverage of rapamycin for healthy aging, where decades of striking mouse lifespan data preceded a completed human trial that missed its primary endpoint. NMN and NR follow the same shape: strong preclinical rationale, a large and growing retail market, and a much smaller, more mixed body of completed human randomized trials.

The trial most often cited to support NMN is a 2021 study published in Science. Researchers randomized 25 postmenopausal women with prediabetes who were overweight or obese to either 250mg/day of NMN (13 women) or an identical-looking placebo (12 women) for 10 weeks. The primary outcome was muscle insulin sensitivity, measured directly with a hyperinsulinemic-euglycemic clamp, the gold standard method for this measurement.^[2]

The result was genuinely positive on that one measure: insulin-stimulated glucose disposal in muscle increased by 25% after NMN, with no change after placebo, and skeletal muscle insulin signaling improved alongside it.^[2]

What is less often repeated is everything else the same trial measured and found no significant NMN-versus-placebo difference in: body composition (fat mass and fat-free mass), blood pressure, fasting glucose and insulin, plasma lipids, hepatic and adipose tissue insulin sensitivity, intrahepatic triglyceride content, mitochondrial respiratory capacity, and physical function measures.^[2]

A single 25-person trial, however well conducted, is not enough to settle whether NMN produces a metabolic benefit. A 2024 systematic review and meta-analysis pooled 8 randomized controlled trials covering 342 adults, mostly middle-aged and older, taking NMN doses of 250mg to 2,000mg/day for 14 days to 12 weeks. Five of those trials reported measurable increases in blood NAD+ levels, confirming NMN does what it is designed to do biochemically.^[3]

On the metabolic outcomes that matter clinically, the pooled result was null. The meta-analysis found no significant benefit on fasting glucose, fasting insulin, or HbA1c, and no significant benefit across the full lipid panel (total, LDL, and HDL cholesterol, and triglycerides). Insulin resistance, measured by HOMA-IR, showed only a borderline signal (a reduction of 0.27, 95% CI -0.01 to 0.55, p=0.06) that became non-significant in a sensitivity analysis.^[3] That is a materially different picture from the single positive Science trial once more data are pooled together.

A separate 2024 systematic review focused specifically on physical performance, pooling 10 randomized controlled trials and 437 participants with a mean age of 58. The authors concluded that NMN supplementation is associated with a nonsignificant improvement in physical strength and aerobic performance. Grip strength moved only marginally (29.9kg to 30.5kg on average across the pooled data), and skeletal muscle mass index was essentially unchanged. A handful of individual trials reported dose-dependent gains in aerobic capacity or walking distance, but those did not add up to a significant effect once all 10 trials were combined.^[4]

This is worth distinguishing from a simple lack of data. Ten trials directly tested whether NMN improves strength or fitness, and the pooled answer was no measurable benefit, which is a meaningfully different (and weaker) evidence position than a claim nobody has tested yet.

The safety data in completed trials is reassuring, within its limits. A randomized, double-blind, placebo-controlled trial gave 31 healthy adults either 1,250mg/day of beta-NMN or placebo for 4 weeks, with clinical assessments at baseline and at weeks 2 and 4. No severe adverse events occurred; five minor events were recorded (loose stool, a common cold, elevated blood pressure, and acne) and judged unrelated to NMN, with all measured clinical parameters staying within normal reference ranges.^[5] The larger 2024 meta-analysis reported a consistent pattern across its pooled safety data, with no significant differences in liver function, blood pressure, or BMI and no severe adverse events.^[3]

The gap is duration. The longest completed trials run about 12 weeks. Nobody has published a multi-year safety dataset for daily NMN or NR use in humans, which matters for a product being marketed as a lifelong anti-aging regimen rather than a short course of treatment.

NMN’s legal status as a supplement has also genuinely flip-flopped in recent years, which is separate from, and should not be confused with, a safety or efficacy finding. The FDA at one point determined NMN was excluded from the legal definition of a dietary supplement because it had already been authorized for investigation as a new drug. After a citizen petition and legal challenge from the Natural Products Association, the agency reversed that position, concluding NMN had been marketed as a supplement before the drug investigation began and was therefore not excluded.^[6]

NMN and NAD+ precursor supplements do one thing with reasonably solid trial support: they raise circulating NAD+ levels within weeks. Whether that translates into a measurable health benefit is a much thinner case than the marketing suggests. A single small trial found a real improvement in muscle insulin sensitivity in prediabetic women, but the larger, more recent pooled evidence, across both metabolic markers and physical performance, found no significant benefit. Short trials show good tolerability, but no completed human trial has tested, let alone demonstrated, that these supplements slow aging or extend healthspan, a point our Longevity & Healthy Aging hub makes about the supplement category generally. See how we grade the strength of evidence across topics in our editorial and evidence standards.

None of this replaces an individual conversation with a clinician who knows your full health history, current medications, and lab values. It reflects what the completed randomized trials actually show as of this writing: a reliable biochemical effect, and a genuinely thin, mixed case for any downstream health benefit.